These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 7257484)

  • 1. [Serum immunoglobulin concentrations in Crohn's disease. Clinical relevance and comparison with lipid-A-antibody titers (author's transl)].
    Kruis W; Paulus W; Fateh-Moghadam A; Schüssler P; Eisenburg J
    Z Gastroenterol; 1981 Jun; 19(6):276-83. PubMed ID: 7257484
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating lipid A antibodies and their relationship to different clinical conditions of patients with Crohn's disease.
    Kruis W; Schussler P; Weinzierl M
    Hepatogastroenterology; 1987 Jun; 34(3):123-6. PubMed ID: 3610019
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Lipid A antibody titers and O antibody titers in Crohn's disease, ulcerative colitis and acute enteritis (author's transl)].
    Schüssler P; Kruis W; Marget W
    Med Klin; 1976 Oct; 71(44):1898-902. PubMed ID: 825710
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Antibody titer to Bacteroides fragilis is increased in Crohn disease patients with fistula development].
    Pietsch M; Brake BA; Schulz TF; Dierich MP
    Z Gastroenterol; 1986 May; 24(5):269-75. PubMed ID: 2425502
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum immunoglobulin M concentrations following bowel resection in chronic inflammatory bowel disease.
    Soltis RD; Wilson ID
    Gastroenterology; 1975 Oct; 69(4):885-92. PubMed ID: 1100468
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Basic fibroblast growth factor as a response parameter to infliximab in fistulizing Crohn's disease.
    Gao Q; Hogezand RA; Lamers CB; Verspaget HW
    Aliment Pharmacol Ther; 2004 Sep; 20(5):585-92. PubMed ID: 15339330
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Lipid A antibody titers in Crohn's disease (author's transl)].
    Schüssler P; Kruis W; Marget W
    Klin Wochenschr; 1976 Nov; 54(21):1055-6. PubMed ID: 994458
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunoglobulin G subclasses in Crohn's disease with and without bowel resection.
    Bures J; Tichý M; Horácek J; Král B; Sobotka L; Cervenka B; Zadák Z; Komárková O; Fixa B; Pidrman V
    Sb Ved Pr Lek Fak Karlovy Univerzity Hradci Kralove; 1993; 36(3):139-47. PubMed ID: 8159910
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Absence of complement fixing antibodies against lipopolysaccharides from Escherichia coli in a subgroup of patients with Crohn's disease.
    Zeitz M; Hope U; Wust B; Galanos C; Möller B; Lawley TJ; Riecken EO
    Gut; 1987 Nov; 28(11):1460-6. PubMed ID: 3322954
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The immunoglobulin concentrations in serum and bowel secretion in patients with Crohn's disease.
    Bergman L; Johansson SG; Krause U
    Scand J Gastroenterol; 1973; 8(5):401-6. PubMed ID: 4201737
    [No Abstract]   [Full Text] [Related]  

  • 11. Immunoglobulins and IgG subclasses in patients with inflammatory bowel disease.
    Gouni-Berthold I; Baumeister B; Berthold HK; Schmidt C
    Hepatogastroenterology; 1999; 46(27):1720-3. PubMed ID: 10430330
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Measles IgM immunoreactivity in patients with inflammatory bowel disease.
    Balzola FA; Khan K; Pera A; Bonino F; Pounder RE; Wakefield AJ
    Ital J Gastroenterol Hepatol; 1998 Aug; 30(4):378-82. PubMed ID: 9789132
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum antibodies to mycobacterial antigens in active Crohn's disease.
    Kobayashi K; Brown WR; Brennan PJ; Blaser MJ
    Gastroenterology; 1988 Jun; 94(6):1404-11. PubMed ID: 2452116
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum angiotensin-converting-enzyme in Crohn's disease.
    Nunez-Gornes JF; Tewksbury DA
    Am J Gastroenterol; 1981 May; 75(5):384-5. PubMed ID: 6267935
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Lipid A antibody titers in patients after ureterosigmoidostomy (author's transl)].
    Tunn U; Senge T; Galanos C
    Urologe A; 1979 Nov; 18(6):332-4. PubMed ID: 505688
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease.
    Maser EA; Villela R; Silverberg MS; Greenberg GR
    Clin Gastroenterol Hepatol; 2006 Oct; 4(10):1248-54. PubMed ID: 16931170
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serologic testing with ANCA, ASCA, and anti-OmpC in children and young adults with Crohn's disease and ulcerative colitis: diagnostic value and correlation with disease phenotype.
    Zholudev A; Zurakowski D; Young W; Leichtner A; Bousvaros A
    Am J Gastroenterol; 2004 Nov; 99(11):2235-41. PubMed ID: 15555007
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating lipid A antibodies despite absence of systemic endotoxemia in patients with Crohn's disease.
    Kruis W; Schussler P; Weinzierl M; Galanos C; Eisenburg J
    Dig Dis Sci; 1984 Jun; 29(6):502-7. PubMed ID: 6144475
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tissue immunoglobulins and early recurrence in Crohn's disease.
    Heimann T; Panveliwalla D; Greenstein A; Cohen A; Smith H; Aufses AH
    Surg Gynecol Obstet; 1982 Apr; 154(4):541-4. PubMed ID: 7064086
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-Saccharomyces cerevisiae mannan antibodies in inflammatory bowel disease: comparison of different assays and correlation with clinical features.
    Annese V; Piepoli A; Perri F; Lombardi G; Latiano A; Napolitano G; Corritore G; Vandewalle P; Poulain D; Colombel JF; Andriulli A
    Aliment Pharmacol Ther; 2004 Nov; 20(10):1143-52. PubMed ID: 15569117
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.